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Neuropathic pain is defined as pain arising as a direct consequence of a lesion or a disease affecting the somato-
sensory system and it affects around 1 in 4 diabetic patients in the UK. The purpose of this genome-wide associ-
ation study (GWAS)was to identify genetic contributors to this disorder. Cases of neuropathic pain were defined
as diabetic patients with a multiple prescription history of at least one of five drugs specifically indicated for the
treatment of neuropathic pain. Controls were diabetic individuals who were not prescribed any of these drugs,
nor amitriptyline, carbamazepine, or nortriptyline. Overall, 961diabetic neuropathic pain cases and 3260diabetic
controls in the Genetics of Diabetes Audit and Research Tayside (GoDARTS) cohort were identified. We found a
cluster in the Chr1p35.1 (ZSCAN20-TLR12P) with a lowest P value of 2.74 × 10−7 at rs71647933 in females and a
cluster in the Chr8p23.1, next to HMGB1P46 with a lowest P value of 8.02 × 10−7 at rs6986153 in males. Sex-
specific narrow sense heritability was higher in males (30.0%) than in females (14.7%). This GWAS on diabetic
neuropathic pain provides evidence for the sex-specific involvement of Chr1p35.1 (ZSCAN20-TLR12P) and
Chr8p23.1 (HMGB1P46) with the disorder, indicating the need for further research.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Neuropathic pain is defined by the International Association for the
Study of Pain as pain arising as a direct consequence of a lesion or a
disease affecting the somatosensory system (Jensen et al., 2011). The
prevalence of neuropathic pain is estimated to be around 7% in a general
population while in a diabetic population around 1 in 4 patients will
suffer from this disorder (van Hecke et al., 2014; Abbott et al., 2011).
The current treatment of neuropathic pain is far from satisfactory,
with fewer than 30% of patients achieving satisfactory relief of diabetic
neuropathic pain (Barrett et al., 2007). Compared to people without
pain and patients with non-neuropathic pain, diabetic neuropathic
pain has a significant negative effect on patients' quality of life (Davies
et al., 2006). In addition, the disorder represents a significant economic
burden to healthcare systems (Tarride et al., 2006; Dworkin et al.,
2010).
Cross-sectional epidemiological studies have identifiedmultiple risk
factors for neuropathic pain. These include older age, female gender,
manual occupation, lower educational attainment, and living in a rural
area or in poor accommodation (Smith et al., 2007; Torrance et al.,
2006). These risk factors are difficult to modify and are not suitable for
clinical intervention, though they are still of academic and political in-
terest. Specifically for diabetic neuropathic pain, modifiable risk factors
including smoking, hypertension, obesity, hypercholesterolemia and
duration of diabetes have been identified (Jensen et al., 2006; Tesfaye
et al., 2005). Unfortunately, there are no published clinical trials that
suggest a reduction in the incidence or severity of neuropathic pain
through addressing these modifiable risk factors. Further effort is re-
quired in this area. Studies have found that, although glycaemic control
can reduce the incidence of diabetic neuropathy, there is limited impact
in decreasing the incidence of accompanying neuropathic pain, even
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with long-term excellent glycaemic control (Callaghan et al., 2012;
Marti et al., 2006). Epidemiological studies, such as genetic association
studies, can identify independent risk factorswhich are clinically impor-
tant, and offer these risk factors as covariates for basic research studies,
or as new factors to address clinically.
Diabetic neuropathic pain is considered as a complex trait which is
affected by both environmental risk factors and genetic risk factors.
Unlike well documented environmental risk factors, the understanding
of the genetic contributors to neuropathic pain is rather poor, though
evidence from animal models and human studies have both confirmed
that it is a heritable trait (Devor et al., 2005; Meng et al., 2015). Studies
on animal models have proposed candidate genes for neuropathic pain
such as P2X7, P2X4, TLR4, and CACNG2 (Chessell et al., 2005; Trang et al.,
2009; Nissenbaum et al., 2010; Wang et al., 2013). The first genome-
wide association study (GWAS) on diabetic neuropathic pain in humans
reported that GFRA2 might be associated with a subgroup of this
disorder (Meng et al., 2015). All these candidate genes need further
replications to validate their biological roles.
We conducted a population-based GWAS of diabetic neuropathic
pain in which our case definition was matched with previous
population-based observational studies of diabetic neuropathic pain
(Hall et al., 2013; Dieleman et al., 2008), seeking candidate genes that
might not have been identified using the previous, more exclusive
case definition (Meng et al., 2015).
2. Methods
2.1. Resources
Genetic resources: The Genetics of Diabetes Audit and Research
Tayside (GoDARTS) project recruits diabetic patients and non-diabetic
matched controls in Tayside, Scotland to identify genetic contributors
relating to the susceptibility of diabetes, the complications of diabetes,
the response to diabetes treatment and the prognosis of diabetes.
(http://diabetesgenetics.dundee.ac.uk/). So far, the project has recruited
9439 diabetic patients who have provided their DNA samples along
with written consent to use their clinical data and biological samples
for research. Among these 9434 diabetic individuals, 3673 were geno-
typed by Affymetrix SNP6.0 chips supported by the Wellcome Trust
Case Control Consortium 2 (WTCCC2) project (http://www.wtccc.org.
uk/ccc2/) and 3254 were genotyped by Illumina OmniExpress chips
supported by the Surrogate markers for Micro- and Macro-vascular
hard endpoints for Innovative diabetes Tools (SUMMIT) project
(http://www.imi-summit.eu/). The GoDARTS study was approved by
Tayside Committee onMedical Research Ethics (REC reference 053-04).
E-health resources: Since 1993, every person registered with the
National Health Service (NHS) in Scotland has been assigned a unique
Community Health Index (CHI) number. This number appears in the re-
cords of all personalmedical activitieswithin theNHS frameworkwhich
paves the way for anonymous data linkage. The GoDARTS project in-
cludes consent fromparticipants for the genetic data to be anonymously
linked with datasets sourced from participants' NHS medical histories,
including prescribing data, blood test results, radiology examination re-
sults, hospital admissions, and outpatient appointments. The current
prescription history dataset used in this study covers from Jan, 1993 to
Dec, 2013.
3. Definitions of Cases and Controls of Neuropathic Pain
In this study, we defined a neuropathic pain case as a type 2 diabetic
patient who has a history of multiple usages (minimum twice) of at
least one of the following five medicines which are recommended and
effective in diabetic peripheral neuropathy andprescribeduncommonly
for other disorders: duloxetine, gabapentin, pregabalin, capsaicin cream
(or patch) and lidocaine patch (Attal et al., 2010; National Institute for
Health & Care Excellence NICE (UK), 2013; Finnerup et al., 2010).
A control was defined as a type 2 diabetic patient who has not been
prescribed any of these five drugs before. Individuals who had a pre-
scription history of amitriptyline, carbamazepine, or nortriptyline
were not included as controls because these drugs are often used for
the treatment of other medical conditions, as well as neuropathic pain.
In other words, diabetic individuals using these drugs could be correctly
classified as neuropathic pain cases or wrongly classified if these drugs
were used for treating other disorders such as depression or epilepsy.
It is not possible to differentiate these two situations with certainty
based on the available clinical information. To avoid the potential for
incorrect phenotyping, those individuals were also removed from the
control group.
We excluded individuals with a history of only one single prescrip-
tion for any of these five drugs from both cases and controls.
3.1. Genotyping and Quality Control
The quality control steps of the genotype data were applied based
on the standard methods that were used for the WTCCC2 studies
(GoDARTS & UKPDS Diabetes Pharmacogenetics Study Group et al.,
2011), and the SUMMIT studies (Fagerholm et al., 2012).
3.2. Statistical Analysis
Non-genotyped single nucleotide polymorphisms (SNPs) in the
Affymetrix SNP6.0 chips and Illumina OmniExpress chipswere imputed
by SHAPEIT and IMPUTE2 based on shared reference files from the 1000
genome phase I datasets (Delaneau et al., 2011; Howie et al., 2009). An
r2 score was used to assess the accuracy of an imputed genotype. It is
suggested to adopt an r2 N 0.3 to remove imputed SNPs with poor qual-
ity. PLINK was the main GWAS software for genetic data manipulation
and standardised quality control steps were frequently performed dur-
ing analyses (For example, SNPs with over 10% genotyping missing
were excluded, SNPs with minor allele frequency less than 1% were re-
moved, SNPs which failed Hardy-Weinberg tests (P b 0.000001) were
removed, and individuals with more than 10% genotype data missing
were not included) (Purcell et al., 2007). SNPs on the sex chromosomes
and mitochondrial SNPs were not included in the analyses since we do
not have these data. The detection of individuals with different ancestry
was done by the multidimensional scaling method implanted in PLINK.
A lambda value generated by this method indicates the level of popula-
tion stratification. The lambda value should be very close to 1 in a
homogeneous population with little ancestry mixture. Related samples
were identified by calculating pi-hat values greater than 0.125 in PLINK.
Logistic regression analyses were applied to generate P values for SNP
association tests. A P value of less than 10−6 was considered to be a sug-
gestive association, worth further exploration. SNP functional annota-
tion was searched by SNPnexus and Manhattan plots were generated
by HaploView (Barrett et al., 2005; Dayem Ullah et al., 2013). Regional
visualisation was achieved by LocusZoom (Pruim et al., 2010). The
Q–Q plot of P values, a tool to assess whether there are confounders
and the impact of these potential confounders (different genotyping
machines, different genotyping chips, different DNA extraction
methods, etc) between cases and controls, was visualised by SNPEVG
(Wang et al., 2012). The whole workflow is summarised in Fig. 1.
Narrow-sense heritabilities of the overall dataset and sex-specific
dataset were performed by restricted maximum likelihood analysis
using the recognized approach to genome-wide complex trait analysis
(GCTA) (Lee et al., 2011). Narrow-sense heritability represents the
ratio of total phenotypic variance which is caused by additive genetic
effects of individual SNPs (Lee et al., 2011). Comparisons of means of
age and BMI between cases and controls were performed using
independent t test in SPSS 21 (IBM Corp, New York, USA). The gender
difference was evaluated using chi-square (2 × 2 tables).
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4. Results
We identified 1043 diabetic patients who had a prescription record
of minimum twice usage of at least one of the five relevant neuropathic
pain drugs (Duloxetine, Gabapentin, Pregabalin, Capsaicin cream
(or patch) and Lidocaine patch, see Methods section for details)
among the genotyped diabetic population of the GoDARTS project,
representing 15.06% of the cohort. In addition, we found 3759 diabetic
individuals who were identifiable as controls, as they had not been
prescribed any of these five drugs, nor other drugs that can be used (non-
exclusively) to treat neuropathic pain (amitriptyline, carbamazepine, or
nortriptyline). After removing ethnically outlying samples, genetically
related samples, type 1 diabetic samples and thosewhohad had a single
prescription of neuropathic pain drugs, the final cohort for analysis
comprised 961 neuropathic pain cases (male = 470, female = 491)
and 3260 controls (male = 2021, female = 1239). We then derived
data summarising the age and body mass index (BMI) for the overall
dataset, male only dataset and female only dataset (Table 1). In the
overall dataset, the average age (mean ± standard deviation, years)
and BMI (mean ± standard deviation, kg/m2) in cases were 72.60 ±
10.54, and 27.79 ± 6.01, respectively. The average age and BMI in con-
trols were 75.51 ± 10.79, and 26.91 ± 5.51, respectively. There were
statistically significant differences in age and BMI between cases and
controls as well as in gender (P b 0.01). In the male only dataset, the
average age and BMI in cases were 72.71 ± 9.96, and 27.06 ± 5.01,
respectively. The average age and BMI in controls were 74.82 ± 10.69,
and 26.83 ± 4.94, respectively. There was no statistical difference in
BMI between cases and controls, but the difference in age was statisti-
cally significant (P b 0.01). In the female only dataset, the average age
and BMI in cases were 72.48 ± 11.08, and 28.49 ± 6.56, respectively.
The average age and BMI in controls were 76.63 ± 10.90, and
27.06 ± 6.33, respectively. The differences in age and BMI between
cases and controls were statistically significant (P b 0.01).
Altogether 6,906,962 genotyped and imputed SNPs survived for
analysis, after standardised quality control of genotyping and imputa-
tion (r2 N 0.3). Since the lambda value (indicating the level of population
stratification)was 1.014 for the cleaned overall dataset, no extra adjust-
ment was adopted based on population stratification. Using logistic
regression testing, with age, sex, and BMI as covariates for the overall
dataset, there was a peak showing in chromosome 1 on the Manhattan
plot (Fig. 2). The associated Q–Q plot is shown in Supplementary File 1.
Although none of the SNPs reached formal genome-wide significance
(5 × 10−8), the cluster in Chromosome 1p35.1 (Chr1p35.1), spanning
ZSCAN20-TLR12P area, still indicated possible associations. The most
significant SNP in this region was rs35260355 in the ZSCAN20 with a
lowest P value of 3.84 × 10−7 and an odds ratio (OR) of 1.66 (95%
confidence interval: 1.37–2.02). Similar logistic regression in the female
only dataset found that the peak in the Chr1p35.1 still existed and the
top SNP rs71647933 in the ZSCAN20 achieved a lower P value of
2.74 × 10−7 with an OR of 2.31 (95% confidence interval: 1.68–3.17)
(Fig. 3). In themale only dataset, the SNP cluster in the Chr1p35.1 disap-
peared while a new peak showed in the Chr8p23.1, next to HMGB1P46
and the P value of the top SNP rs6986153 was 8.02 × 10−7 with an OR
of 1.67 (95% confidence interval: 1.34–2.08) (Fig. 4). Table 2 summa-
rises all the significant SNPs found in the regions in the three datasets.
Figs. 5 and 6 show the regional plots of the identified loci in the female
only dataset and the male only dataset, respectively. It was estimated
that the narrow-sense heritability of neuropathic pain was 14.7% in
the overall dataset, but 30.0% among males, compared with 14.7%
among females.
5. Discussion
Utilising a genetic dataset and e-health linkage dataset, we per-
formed a GWAS on diabetic neuropathic pain using case and control
definitions matched with previous population-based epidemiological
studies and the results suggested two loci that may be involved with
painful diabetic neuropathy.
Standard protocols of the assessment of neuropathic pain have been
widely agreed for specialist settings and primary care (Haanpää et al.,
2011; Jones & Backonja, 2013). However, there is no common approach
or consensus reached by clinicians or researchers to define neuropathic
pain in population-based settings or in general cohorts. As GoDARTS
participants were recruited through community-based clinics and gen-
eral hospitals, there is no formal record of neuropathic pain statusmade
by specialists. We acknowledge that expert clinical examination would
have increased the robustness of the case definition in this cohort. How-
ever, without clinical examination evidence, it is reasonable to use an
alternative, acceptable definition to represent neuropathic pain cases.
We adopted a pragmatic approach to define cases using a multiple
prescription history of the five main drugs used exclusively or mainly
to treat neuropathic pain (rather than other disorders) in a diabetic
population. A combination of diagnostic codes for type 2 diabetes and
prescription of neuropathic pain drugs has been used in previous
epidemiological studies to identify patients with painful diabetic neu-
ropathy (Hall et al., 2013; Dieleman et al., 2008). Members of our
population-based cohort were already identified as having type 2
diabetes, and so our method of identifying neuropathic pain makes
this study reasonably consistentwith these previous studies.While am-
itriptyline, carbamazepine, and nortriptyline are also frequently used in
neuropathic pain, we considered that these are relatively likely to be
used for indications other than neuropathic pain andwe did not include
individuals who had been prescribed these drugs as either cases or con-
trols. To have amore homogeneous population,we removed individuals
with only a single prescription of the five neuropathic pain drugs from
both cases and controls. It has previously been highlighted that patients
in primary care with neuropathic pain are often not prescribed any of
the specific medications for its treatment (Hall et al., 2008; Torrance
et al., 2007, 2013). As there is no pain status recorded in the GoDARTS,
Fig. 1.Workflow of the GWAS on neuropathic pain.
Table 1
Information on covariates between cases and controls.
Cases Controls P value
Overall dataset Age 72.60 ± 10.54 75.51 ± 10.79 b0.01
BMI 27.79 ± 6.01 26.91 ± 5.51 b0.01
Male:Female 470:491 2021:1239 b0.01
Male only Age 72.71 ± 9.96 74.82 ± 10.69 b0.01
BMI 27.06 ± 5.01 26.83 ± 4.94 N0.05
Female only Age 72.48 ± 11.08 76.63 ± 10.90 b0.01
BMI 28.49 ± 6.56 27.06 ± 6.33 b0.01
Age and BMI (body mass index) are presented as mean ± standard deviation.
Age is defined as 2014 — birth year.
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no direct assessment of the presence of (neuropathic) pain can bemade
among cases or controls. Furthermore, we did not assess whether cases
or controls had received any other prescriptions for pain, such as opioid
medications, and it is possible that some with neuropathic pain were
treated with drugs that are not specifically indicated for this. Therefore
the definition in our study is possible to have classified some who have
neuropathic pain as controls but few controls as cases. The subsequent
P values and ORs may be underestimated, though we cannot measure
the extent of this.
The most significant SNP cluster in the overall dataset was found in
Chr1p35.1with a lowest P value of 3.84× 10−7 at rs35260355, spanning
ZSCAN20-TLR12P area. The function of ZSCAN20 (zinc finger and SCAN
domain containing 20) gene is not known yet and it has not been
noted to be associated with any disorders. One of the proteins it codes
contain typical C2H2 zinc finger domain, which enables zinc finger pro-
tein to bind other molecules such as RNA and DNA and affect transcrip-
tion and translation (Krishna et al., 2003). There have been attempts to
use zincfinger proteins to treat neuropathic pain since the receptor spe-
cific transcription factors of zinc-finger proteins have been developed to
target gene repression in cell line models and in vitro (Tan et al., 2005).
It is worth noting that the top SNP from the female only dataset
rs71647933 is suggested to be a transcription factor binding site of the
Fig. 2.Manhattan plot of the GWAS on neuropathic pain in the overall dataset. X axis represents 22 autosomes. Y axis means the –log10 of P values. The blue line is the cut-off P value of
10−6. Cases and controls included 961 and 3260 samples, respectively. (Only SNPs whose P b 0.01 were used to make the plot).
Fig. 3.Manhattan plot of theGWASonneuropathic pain in the female only dataset. X axis represents 22 autosomes. Y axismeans the–log10 of P values. The blue line is the cut-off P value of
10−6. Cases and controls included 491 and 1239 individuals, respectively. (Only SNPs whose P b 0.01 were used to make the plot).
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zinc interaction domain (SNPnexus). Toll-like receptors (TLRs) are a
class of proteins which exist in various cell types in the central nervous
system, including neuronal and non-neuronal cells (Liu et al., 2012).
TLRs share structural and functional similarities. Specifically, the dele-
tion or inhibition of TLR2 and TLR4 in animal models will impair nerve
injury-induced neuropathic pain (Kim et al., 2007; Tanga et al., 2005).
When using a TLR4 antagonist to treat both wild type mice and TLR4
knockout mice suffering neuropathic pain, pain relief can be achieved
in the wild type mice but not in the TLR4 knockout mice (Bettoni
et al., 2008). TLR12P is a unitary pseudogene with a transcript but
there is no protein product of this gene in the human. The function of
its homolog in mice is unclear although it is suggested it may be in-
volved in the immune system against pathogens (Koblansky et al.,
2012). There is emerging evidence showing that TLRs are involved in
the control of (neuropathic) pain while the mechanisms are still far
from being elucidated (Liu et al., 2012). In the females only dataset
(1730 individuals), the P value of the SNPs in the cluster were lower
than in the overall dataset, indicating that the male samples were not
contributing so much to the associations in this cluster, and that the
identified ZSCAN20-TLR12P locus has a gender specific influence on dia-
betic neuropathic pain. This is consistent with the findings of other TLR
genes. Studies have found that variants in TLR genes are gender-
specifically linked with multiple situations (Roberts et al., 2012). The
mechanism of sex-specific phenomena is not clear and the evidence
for hormone involvement is insufficient and controversial (Roberts
et al., 2012; Berghöfer et al., 2006).
We also identified a peak in the Chr8p23.1 next to HMGB1P46when
analysing the male only dataset, and the P value of the top SNP
rs6986153 was 8.02 × 10−7 with an OR of 1.67. HMGB1P46 is a
pseudogene of high mobility group box-1 (HMGB1). It is suggested
that the induction of high mobility group box-1 in the dorsal root
ganglion can contribute to pain hypersensitivity after peripheral nerve
injury (Shibasaki et al., 2010). In addition, Feldman et al found that
the persistent endogenous release of HMGB1 by sensory neurons
contributes to tactile hyperalgesia in a neuropathic pain rat model
(Feldman et al., 2012). The synthesis and release of HMGB1 from spinal
neurons due to nerve injury facilitates the activity of bothmicroglia and
neuronswhich leads to symptoms of neuropathic pain (Nakamura et al.,
2013). It is interesting to know that HMGB1 signalling and TLR
pathways, to some extent, are overlapping together (Yu et al., 2006;
Velegraki et al., 2012). There is evidence that pseudogenes are involved
in the biological process. For example, the low level of high mobility
group A1 (HMGA1) was also associated with a high level of HMGA1
pseudogene (HMGA1-p) mRNA (Chiefari et al., 2010). It was observed
that knockdown of HMGA1-p RNA in the cells of diabetic patients led
to partially restored HMGA1mRNA levels which suggested a competing
relationship between the two types of transcripts. It is therefore
hypothesised that a competing relationship might also exist between
HMGB1 and its pseudogenes.
Therewere no SNPs foundwith a P value of less than 5 × 10−8 in the
overall dataset, male only or female only datasets. Although a P value
of 5 × 10−8 is generally adopted as the cut-off P value for GWAS
Fig. 4.Manhattan plot of the GWAS on neuropathic pain in themale only dataset. X axis represents 22 autosomes. Y axismeans the –log10 of P values. The blue line is the cut-off P value of
10−6. Cases and controls included 470 and 2021 individuals, respectively. (onLy SNPs whose P b 0.01 were used to make the plot).
Table 2
Significant SNPs in the overall, female only and male only dataset.
Dataset SNP Chr Position Gene Minor allele Minor allele frequency in cases:controls P value OR (95% CI)
Overall rs4652898 1 33940691 ZSCAN20 C 0.19:0.16 7.45 × 10−7 1.63 (1.34–1.98)
rs2336244 1 33943390 ZSCAN20 C 0.18:0.15 9.07 × 10−7 1.67 (1.36–2.05)
rs71647933 1 33945601 ZSCAN20 G 0.19:0.16 4.88 × 10−7 1.65 (1.36–2.02)
rs35260355 1 33945831 ZSCAN20 T 0.19:0.16 3.84 × 10−7 1.66 (1.37–2.02)
Female rs10914731 1 33934824 Intergenic G 0.21:0.16 4.25 × 10−7 2.25 (1.64–3.09)
rs4652898 1 33940691 ZSCAN20 C 0.20:0.16 3.70 × 10−7 2.29 (1.67–3.16)
rs2336244 1 33943390 ZSCAN20 C 0.19:0.15 9.00 × 10−7 2.39 (1.69–3.38)
rs71647933 1 33945601 ZSCAN20 G 0.20:0.16 2.74 × 10−7 2.31 (1.68–3.17)
rs35260355 1 33945831 ZSCAN20 T 0.20:0.16 2.81 × 10−7 2.30 (1.68–3.17)
Male rs6986153 8 108072044 Intergenic G 0.27:0.19 8.02 × 10−7 1.67 (1.34–2.08)
Chr, chromosome; SNP, single nucleotide polymorphisms; OR, odds ratio; 95% CI, 95% confidence interval.
P values and ORs were calculated using logistic regression test.
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significance, it has been suggested that this might be too stringent and
risks missing important associations (i.e. false negatives) (Do et al.,
2014). Using a lower threshold raises the chance of detecting associated
SNPs, but also of detecting spurious associations (false positives), and
we need to beware of that in interpreting this study. The narrow-
sense heritability (variance explained by SNPs, excluding genetic
variation due to dominance, epistasis, and environment) of diabetic
neuropathic pain in the overall dataset was estimated to be 14.7%,
which is similar to that found in our previous analysis (Meng et al.,
2015). However when calculated by gender, we found males had a
higher heritability (30.0%) than females (14.7%). Sex-specific heritabili-
ty has been observed in other traits (Weiss et al., 2005). The reasons
behind the different gender-specific heritabilities are unknown
although it may result from parent-of-origin effects, interaction with
sex chromosomes and the sex-specific hormonal environment. It is
worth considering sex-specific genetic effects in future association stud-
ies of neuropathic pain. There are some reports indicating that genetic
effects are different between genders in determining pain. Experiments
in mice found that the Mc1r gene mediates kappa-opioid analgesia in
female mice only. Correspondingly in a human study, females with
two variantMC1R alleles showed greater analgesic responses from the
kappa-opioid, pentazocine, than males and females who did not have
the variant alleles (Mogil et al., 2003). In addition, polymorphisms in
the OPRM1 gene have been reported to be associated with pressure-
related pain sensitivity in men but not in women (Fillingim et al.,
2005). Sato et al found that there were significant associations between
the opioid receptor genes (OPRM1, OPRD1 and opioid OPRK1) and
experimental pain sensitivity (Sato et al., 2013). Our results showing
genetic differences associated with neuropathic pain between genders
are consistent with these findings, though the biological mechanisms
remain unclear and highlight the need for further research in this
area. The heritability of neuropathic pain has been calculated as around
30% in rat models (Devor et al., 2005), similar to that measured here
among men, though twice that found among women..
Using an additive model integrated in the CaTS, we had 80% power
for the overall dataset (961 cases and 3260 controls), assuming a
minor disease allele frequency of 0.20, a genotypic relative risk for this
variant of 1.31, a prevalence of neuropathic pain in the diabetic popula-
tion of 0.25, and the significance level is 10−6 (Skol et al., 2006). In our
previous analysis, our case definition also included evidence of neurop-
athy, based on recorded results of monofilament testing (Meng et al.,
2015). As we did not consider the results of monofilament testing in
this study, our case definitionwasmore inclusive and therefore less spe-
cific. Although there are power benefits of includingmore cases, there is
also a possibility that neuropathic pain with and without neuropathy
evidencemight have separate genetic riskmarkers, aswell as shared ge-
netic mechanisms. No studies have been reported examining whether
there is any genetic difference between neuropathic pain with and
without neuropathy evidence. The peaks we have identified in this
paper could reflect some ‘general’ genetic mechanisms of neuropathic
pain while the different peaks identified in our previous GWAS may
be specifically associated with neuropathic pain with neuropathy
evidence (Meng et al., 2015). In other disorders, a phenotype and its
subtypes have been shown to have both shared and different genetic
risks (Kessler et al., 2013). Similarly, we did not remove those who
were prescribed strong opioid drugs from the control group since opioid
drugs are neither indicated first- or second-line treatments, nor com-
monly used to treat diabetic neuropathic pain (Torrance et al., 2013).
A good phenotype, endophenotype and subgroup definition should
aim to reflect the underlying genetic mechanisms.
There are some recent GWAS published in the field of pain research.
A locus between CCT5 and FAM173B located at Chr5p15.2 has been pro-
posed to be associated with chronic widespread pain (Peters et al.,
2013). TAOK3 was suggested to be associated with morphine require-
ment and postoperative pain in a retrospective paediatric day surgery
population (Cook-Sather et al., 2014). Rs11127292 in the MYT1L was
found to be associated to fibromyalgia with low comorbidities
(Docampo et al., 2014). Another GWAS study suggested rs2952768 in
the Chr2q33.3 was involved with analgesic requirements in humans
(Nishizawa et al., 2014). These GWAS have shed light on the elucidation
of the genetic pathways for pain while further research is needed,
including replication studies, functional studies, and agreement on
feasible, valid and reproducible phenotype ascertainment.
The limitations of our study include that the P values of tops SNPs are
only close to GWAS significance but yet reached; no replication study to
confirm the results; though the case definition is matched with those
used epidemiological studies, we might misclassify some cases who
have neuropathic pain but not prescribed medications into controls;
we might also misclassify an individual into a control group who uses
opioid to treat neuropathic pain.
We have provided genetic evidence that SNPs in Chr1p35.1
(ZSCAN20-TLR12P) and Chr8p23.1 (HMGB1P46) may be involved with
neuropathic pain in diabetes. Sex-specific associations are also sug-
gested. Our findings should be treated with caution and, while we
have also presented their consistency with known biological factors,
they can only guide the nature of future research, which will be based
on the findings reported in this paper. Any replication of our findings
will help to confirm hypothesised pathways involved in the genetic
Fig. 5. Regional plot of Chr1p35.1 in females. r2 represents the linkage disequilibrium
among SNPs.
Fig. 6. Regional plot of Chr8p23.1 inmales. r2 represents the linkage disequilibrium among
SNPs.
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mechanisms of neuropathic pain and provoke research on new poten-
tial drug targets for the treatment of pain.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.08.001.
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